title: Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy.
abstract: BACKGROUND
  Choroidal neovascularization (CNV) is well recognized as a complication of laser photocoagulation for central serous chorioretinopathy (CSC). However, little is known about its management.
  
  
  METHODS
  Two patients who developed iatrogenic CNV after laser photocoagulation for CSC.
  
  
  METHODS
  A single intravitreal bevacizumab (IVB) injection was given in both cases. The best-corrected visual acuity (BCVA) of 1 of the patients improved from 0.3 to 0.5 on the following day and to 1.2 three months after the IVB, and the BCVA of the other patient improved from 0.5 to 1.0 two weeks after the IVB. In both cases, the CNV became inactive 1 month after IVB on fluorescein angiography and remained stable for over 1 year.
  
  
  CONCLUSIONS
  IVB was beneficial for iatrogenic CNV that developed after laser photocoagulation for CSC.
authors.affiliation: Department of Ophthalmology, University of Tokyo School of Medicine, 7-3-1 Hongo, Tokyo, 113-8655, Japan. nomurayoko-tky@umin.ac.jp
authors.forename: Yoko
authors.initials: Y
authors.lastname: Nomura
authors.forename: Ryo
authors.initials: R
authors.lastname: Obata
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yanagi
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000601:surgery*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005451:Fluorescein Angiography; D006801:Humans; D007049:Iatrogenic Disease; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab